An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia

Gertjan J. L. Kaspers, Denise Niewerth, Bram A. J. Wilhelm, Peggy Scholte-van Houtem, Marta Lopez-Yurda, Johannes Berkhof, Jacqueline Cloos, Valerie de Haas, Ron A. Mathôt, Andishe Attarbaschi, André Baruchel, Eveline S. de Bont, Franca Fagioli, Claudia Rössig, Thomas Klingebiel, Barbara de Moerloose, Brigitte Nelken, Giuseppe Palumbo, Dirk Reinhardt, Pierre-Simon RohrlichPauline Simon, Arend von Stackelberg, Christian Michel Zwaan

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)


This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m2/dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3–4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.
Original languageEnglish
Pages (from-to)523-527
Number of pages5
JournalBritish journal of haematology
Issue number4
Publication statusPublished - 1 May 2018


  • acute leukaemia
  • bortezomib
  • childhood leukaemia
  • pharmacokinetics
  • proteasome inhibitor

Cite this